Minerva Neurosciences, Inc. NERV
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Minerva Neurosciences, Inc. (NERV) is a healthcare company listed in the US with a market value of about $115M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -549%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 77% below the current price.
About Minerva Neurosciences
Minerva Neurosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. It was profitable in 2 of the last 10 years in our data. Its share count rose by 58% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $41M | $0 | $0 | $0 | — |
| Net income | -$293M | $1M | -$30M | -$32M | -$50M | $2M | -$72M | -$50M | -$32M | -$31M |
| Free cash flow | — | — | — | -$25M | — | — | — | — | $3M | — |
| EPS (diluted) | $-34.67 | $0.19 | $-4.61 | $-6.01 | $-9.35 | $0.40 | $-14.80 | $-10.32 | $-6.64 | $-7.92 |
| Net margin | — | — | — | — | — | 4.7% | — | — | — | — |
| ROIC | — | — | — | — | -549.0% | 2.8% | -262.2% | -57.3% | -23.4% | -26.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Minerva Neurosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 77% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Minerva Neurosciences pay a dividend?
Not currently.
Is Minerva Neurosciences a good stock to buy?
We do not give buy or sell advice. Minerva Neurosciences scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.